Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034

被引:192
作者
Tong, Xiao [1 ]
Chase, Robert [1 ]
Skelton, Angela [1 ]
Chen, Tong [1 ]
Wright-Minogue, Jackie [1 ]
Malcolm, Bruce A. [1 ]
机构
[1] Schering Plough Res Inst, Dept Virol, Kenilworth, NJ 07033 USA
关键词
hepatitis C virus; protease; inhibitor; resistance; antiviral;
D O I
10.1016/j.antiviral.2005.12.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
HCV NS3 protease variants resistant to the protease inhibitor SCH 503034 were selected. Three mutations, T54A, V170A and A 156S mutations conferred low to moderate levels of resistance (< 20-fold). Longer exposure (> 10 passages) or selection with higher levels of compound led to the selection of a more resistant variant, A156T (> 100-fold). [Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A., Kwong, A.D., 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279(17), 17508-17514; Lu, L., Pilot-Matias, T.J., Stewart, K.D., Randolph, J.T., Pithawalla, R., He, W., Huang, P.P., Klein, L.L., Mo, H., Molla, A., 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48(6), 2260-2266.] Combination with IFN-alpha drastically reduced the number of emergent colonies. Resistant colonies showed no change in sensitivity to IFN-alpha. Although the A156T mutation conferred the highest level of resistance to SCH503034, it significantly reduced the colony formation efficiency (CFE) of the mutant replicon RNA, and rendered replicon cells less fit than those bearing wild-type replicons. Replicon cells bearing mutation A156S were less fit than wild-type in co-culture growth competition assays but showed no impact on CFE. The V170A mutation, on the other hand, did not affect replicon fitness in either assay, which was consistent with its emergence as the dominant mutant after 12 months of continuous selection. The reduced fitness of the most resistant variant suggests that it may be rare in naive patients and that development of high-level resistance may be slow. Combination therapy with IFN-alpha should also greatly reduce the potential emergence of resistance. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:28 / 38
页数:11
相关论文
共 43 条
[21]   Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line [J].
Lohmann, V ;
Körner, F ;
Koch, JO ;
Herian, U ;
Theilmann, L ;
Bartenschlager, R .
SCIENCE, 1999, 285 (5424) :110-113
[22]   Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro [J].
Lu, LJ ;
Pilot-Matias, TJ ;
Stewart, KD ;
Randolph, JT ;
Pithawalla, R ;
He, WP ;
Huang, PP ;
Klein, LL ;
Mo, HM ;
Molla, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2260-2266
[23]   Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to 150V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro [J].
Maguire, MF ;
Guinea, R ;
Griffin, P ;
Macmanus, S ;
Elston, RC ;
Wolfram, J ;
Richards, N ;
Hanlon, MH ;
Porter, DJT ;
Wrin, T ;
Parkin, N ;
Tisdale, M ;
Furfine, E ;
Petropoulos, C ;
Snowden, BW ;
Kleim, JP .
JOURNAL OF VIROLOGY, 2002, 76 (15) :7398-7406
[24]  
MALCOLM BA, IN PRESS ANTIMICROB
[25]   Resistance-associated loss of viral fitness in human immunodeficiency virus type 1:: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients [J].
Mammano, F ;
Petit, C ;
Clavel, F .
JOURNAL OF VIROLOGY, 1998, 72 (09) :7632-7637
[26]   Estimating relative fitness in viral competition experiments [J].
Marée, AFM ;
Keulen, W ;
Boucher, CAB ;
De Boer, RJ .
JOURNAL OF VIROLOGY, 2000, 74 (23) :11067-11072
[27]   SELECTION AND ANALYSIS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I VARIANTS WITH INCREASED RESISTANCE TO ABT-538, A NOVEL PROTEASE INHIBITOR [J].
MARKOWITZ, M ;
MO, HM ;
KEMPF, DJ ;
NORBECK, DW ;
BHAT, TN ;
ERICKSON, JW ;
HO, DD .
JOURNAL OF VIROLOGY, 1995, 69 (02) :701-706
[28]   HEPATITIS-C VIRUS (HCV) CIRCULATES AS A POPULATION OF DIFFERENT BUT CLOSELY RELATED GENOMES - QUASI-SPECIES NATURE OF HCV GENOME DISTRIBUTION [J].
MARTELL, M ;
ESTEBAN, JI ;
QUER, J ;
GENESCA, J ;
WEINER, A ;
ESTEBAN, R ;
GUARDIA, J ;
GOMEZ, J .
JOURNAL OF VIROLOGY, 1992, 66 (05) :3225-3229
[29]   Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants [J].
Martinez-Picado, J ;
Savara, AV ;
Shi, L ;
Sutton, L ;
D'Aquila, RT .
VIROLOGY, 2000, 275 (02) :318-322
[30]   Ordered accumulation of mutations in HIV protease confers resistance to ritonavir [J].
Molla, A ;
Korneyeva, M ;
Gao, Q ;
Vasavanonda, S ;
Schipper, PJ ;
Mo, HM ;
Markowitz, M ;
Chernyavskiy, T ;
Niu, P ;
Lyons, N ;
Hsu, A ;
Granneman, GR ;
Ho, DD ;
Boucher, CAB ;
Leonard, JM ;
Norbeck, DW ;
Kempf, DJ .
NATURE MEDICINE, 1996, 2 (07) :760-766